Evidence map›Paper›PMID 35699780›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy: a longitudinal feasibility study.

Priscilla Gates, Meinir Krishnasamy, Carlene Wilson, Eliza A Hawkes, Vincent Doré, Yuliya Perchyonok, Christopher C Rowe, Adam K Walker, Janette L Vardy, Michiel B de Ruiter and 3 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Cognitive impairment is associated with altered blood cell profiles in aggressive lymphoma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Priscilla GatesDepartment of Clinical Haematology, Austin Health, Melbourne, Victoria, Australia. Priscilla.Gates@petermac.org.ORCID http://orcid.org/0000-0002-7978-5802
Meinir KrishnasamyDepartment of Nursing, Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-3050-4213
Carlene WilsonOlivia Newton-John Cancer Wellness and Research Centre, Austin Health, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-1883-4690
Eliza A HawkesDepartment of Clinical Haematology, Austin Health, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-0376-2559
Vincent DoréDepartment Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia.
Yuliya PerchyonokFaculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
Christopher C RoweFaculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
Adam K WalkerNeuroscience Research Australia, Sydney, New South Wales, Australia.
Janette L VardyFaculty of Medicine and Health, University of Sydney, Sydney, Australia.
Michiel B de RuiterNetherlands Cancer Institute, Amsterdam, The Netherlands.
Tania CushionDepartment of Clinical Haematology, Austin Health, Melbourne, Victoria, Australia.
Haryana M Dhillon *Faculty of Science, School of Psychology, Centre for Medical Psychology& Evidence-Based Decision-Making, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-0252-2203
Karla Gough *Department of Nursing, Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-2819-4217

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCancer-related cognitive impairment (CRCI) is a recognised adverse consequence of cancer and its treatment. This study assessed the feasibility of collecting longitudinal data on cognition in patients with newly diagnosed, aggressive lymphoma undergoing standard therapy with curative intent via self-report, neuropsychological assessment, peripheral markers of inflammation, and neuroimaging. An exploration and description of patterns of cancer-related cognitive impairment over the course of treatment and recovery was also undertaken and will be reported separately.

methodsEligible participants completed repeated measures of cognition including self-report and neuropsychological assessment, and correlates of cognition including blood cell-based inflammatory markers, and neuroimaging at three pre-specified timepoints, time 1 (T1) - pre-treatment (treatment naïve), time 2 (T2) - mid-treatment, and time 3 (T3) - 6 to 8 weeks post-completion of treatment.

results30/33 eligible patients (91%, 95% CI: 76%, 97%) were recruited over 10 months. The recruitment rate was 3 patients/month (95% CI: 2.0, 4.3 patients/month). Reasons for declining included feeling overwhelmed and rapid treatment commencement. Mean age was 57 years (SD = 17 years) and 16/30 (53%) were male. Most patients (20/30, 67%) had diffuse large B cell lymphoma or Hodgkin lymphoma (4/30, 13%). The neuroimaging sub-study was optional, 11/30 participants (37%) were eligible to take part, and all agreed. The remaining 19 participants were ineligible as their diagnostic PET/CT scan was completed prior. Retention and compliance with all assessments were 89 to 100% at all timepoints. Only one participant was withdrawn due to disease progression.

conclusionsFindings from this study including excellent recruitment, retention, and compliance rates demonstrate it is feasible to longitudinally assess cognition in people with newly diagnosed aggressive lymphoma during their initial treatment and recovery to inform the development of future research to improve patient experiences and cognitive outcomes.

trial registrationAustralian New Zealand Clinical Trials Registry ACTRN12619001649101.

Indexed as

Cognitive DysfunctionLymphoma, Non-HodgkinAdultAgedAustraliaFeasibility StudiesFemaleHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyAggressive lymphomaCancer-related cognitive impairmentFeasibility study

Identifiers

PMID35699780
PMCPMC9385796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.